Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to 6.2%.

  • Pharma-Bio Serv's EBIT Margin rose 4100.0% to 6.2% in Q4 2025 from the same period last year, while for Oct 2025 it was 7.08%, marking a year-over-year increase of 64600.0%. This contributed to the annual value of 7.08% for FY2025, which is 64600.0% up from last year.
  • Latest data reveals that Pharma-Bio Serv reported EBIT Margin of 6.2% as of Q4 2025, which was up 4100.0% from 15.99% recorded in Q3 2025.
  • Over the past 5 years, Pharma-Bio Serv's EBIT Margin peaked at 10.06% during Q3 2023, and registered a low of 85.72% during Q4 2021.
  • For the 5-year period, Pharma-Bio Serv's EBIT Margin averaged around 5.06%, with its median value being 1.1% (2023).
  • As far as peak fluctuations go, Pharma-Bio Serv's EBIT Margin tumbled by -887400bps in 2021, and later surged by 893600bps in 2022.
  • Over the past 5 years, Pharma-Bio Serv's EBIT Margin (Quarter) stood at 85.72% in 2021, then soared by 104bps to 3.64% in 2022, then crashed by -139bps to 1.44% in 2023, then tumbled by -359bps to 6.61% in 2024, then grew by 6bps to 6.2% in 2025.
  • Its EBIT Margin was 6.2% in Q4 2025, compared to 15.99% in Q3 2025 and 4.07% in Q2 2025.